A Randomised, Double-Blind, Parallel-Group, Multicentre, Phase III Study Comparing the Efficacy and Tolerability of Fulvestrant (FASLODEX) 500 mg With Fulvestrant (FASLODEX) 250 mg in Postmenopausal Women With Oestrogen Receptor Positive Advanced Breast Cancer Progressing or Relapsing After Previous Endocrine Therapy

Trial Profile

A Randomised, Double-Blind, Parallel-Group, Multicentre, Phase III Study Comparing the Efficacy and Tolerability of Fulvestrant (FASLODEX) 500 mg With Fulvestrant (FASLODEX) 250 mg in Postmenopausal Women With Oestrogen Receptor Positive Advanced Breast Cancer Progressing or Relapsing After Previous Endocrine Therapy

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 21 Jun 2017

At a glance

  • Drugs Fulvestrant (Primary)
  • Indications Advanced breast cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms CONFIRM
  • Sponsors AstraZeneca
  • Most Recent Events

    • 25 May 2017 Planned End Date changed from 1 Jan 2018 to 5 Jan 2018.
    • 07 Nov 2016 Planned End Date changed from 1 Jan 2017 to 1 Jan 2018.
    • 16 May 2016 Results of a sub-group analysis (n=134) published in the Clinical cancer research: an official journal of the American Association for Cancer Research
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top